Medicus Pharma Ltd. has announced the submission of a comprehensive product development plan to the Food and Drug Administration (FDA) to treat external squamous cell carcinoma $(SCC)$ in horses. This plan involves the use of a novel Doxorubicin-containing microneedle array (D-MNA) patch, which in December 2024 received a Minor Use in Major Species Designation (MUMS). The submission aims to seek the FDA's concurrence under the MUMS designation, advancing the company's efforts in veterinary oncology. This development is part of Medicus Pharma's broader initiative to innovate treatment options in veterinary medicine.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.